Citius Pharmaceuticals, Inc., (Nasdaq: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of drug products that address important unmet medical needs. Citius Pharmaceuticals, Inc., recently acquired an exclusive option with privately held Novellus, Inc., to license a novel stem-cell therapy for Acute Respiratory Distress Syndrome (ARDS) associated with Covid-19. The company focuses on adjunctive cancer therapies, critical-care medicine, and anti-infectives. Citius Pharmaceuticals, Inc., is focused on obtaining intellectual property protection for a significant post-approval period and also seeks to identify regulatory opportunities for market exclusivity. The company is advancing three product candidates: 1) Mino-Lokis in Phase III trials and is enrolling patients, 2) Halo-Lido (CITI-002) is being prepared for a Phase IIb trial, and 3) Mino-Wrap(CITI-101) is in pre-clinical stage. The markets for these products are large, underserved, and provide unique opportunities for the company. Mino-Lok and Mino-Wrap are the results of collaborations with MD Anderson Cancer Center. Founders and company officers have cumulatively invested $26.5 million into the company.